Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINIER phase 3 trial of povetacicept in adults with IgA nephropathy
MOH_2024-11-10_013720Phase 3Active, not recruiting
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of povetacicept in IgA nephropathy (IgAN), sponsored by Alpine Immune Sciences, Inc. Primary endpoint: Primary endpoint not reported. Started Nov 2024; status: active, not recruiting.
02
Drugs
povetacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2024-11-10_013720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-10_013720.